Alcon (XSWX:ALCE) Forward PE Ratio: 19.76 (As of Jun. 25, 2026)


XSWX:ALCE Alcon Inc XSWX:ALCE
53 GF Score
Price CHF55.60
GF Value CHF73.46
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Alcon Forward PE Ratio?

Alcon XSWX:ALCE +3.65% 53 Forward PE Ratio is 19.76 as of Jun. 25, 2026. GuruFocus rates XSWX:ALCE with a GF Score™ of 53/100 and a GF Value™ of CHF73.46 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 393 Medical Devices & Instruments companies, Alcon ranks worse than 53.69% on this metric.

Alcon's Forward PE Ratio for today is 19.76.

Alcon's PE Ratio without NRI for today is 21.76.

Alcon's PE Ratio (TTM) for today is 41.68.


Alcon  (XSWX:ALCE) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Alcon Forward PE Ratio Related Terms


Alcon Forward PE Ratio Historical Data

* Premium members only.

The historical data trend for Alcon's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alcon Forward PE Ratio Chart

Alcon Annual Data
Trend
Forward PE Ratio

Alcon Quarterly Data
Forward PE Ratio

XSWX:ALCE vs ISRG, BDX, MDLN: Forward PE Ratio Comparison

For the Medical Instruments & Supplies subindustry, Alcon's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alcon Forward PE Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Alcon's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Alcon's Forward PE Ratio falls into.


XSWX:ALCE
53GF Score
Alcon Inc XSWX:ALCE
Forward PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alcon Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

Frequently Asked Questions Learn more about Forward PE Ratio →
What does a Forward PE Ratio of 19.76 mean?
Alcon (XSWX:ALCE) has a Forward PE Ratio of 19.76 as of Jun. 25, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Alcon and its competitors. According to the industry distribution chart, Alcon ranks #211 out of 393 companies in the Medical Devices & Instruments industry, placing it in the top 53.7%.
Is Alcon's Forward PE Ratio too high?
Alcon's current Forward PE Ratio is 19.76. The Medical Devices & Instruments industry median Forward PE Ratio is 18.85. Alcon's value of 19.76 is 4.8% above this industry median. Based on the distribution chart, Alcon ranks #211 out of 393 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Alcon has a GF Score™ of 53/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alcon's Forward PE Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Alcon ranks #211 out of 393 companies for Forward PE Ratio. This places Alcon in the lower half of its industry. The industry median Forward PE Ratio is 18.85. Alcon's value of 19.76 is 4.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Medical Devices & Instruments company?
The median Forward PE Ratio among Medical Devices & Instruments companies is 18.85, based on 393 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alcon's current Forward PE Ratio of 19.76 is 4.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Alcon and its competitors. For the Medical Devices & Instruments industry, the median Forward PE Ratio is 18.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alcon's current Forward PE Ratio is 19.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alcon stock overvalued right now?
Based on GuruFocus' analysis, Alcon (XSWX:ALCE) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF73.46, compared to a current price of CHF55.60 — trading 24.3% below its estimated fair value. The current Forward PE Ratio is 19.76 and 4.8% above the Medical Devices & Instruments industry median of 18.85. Alcon's overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Alcon (XSWX:ALCE), the current Forward PE Ratio is 19.76 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alcon (XSWX:ALCE) Overvalued in 2026?

Based on GuruFocus' analysis, Alcon stock appears to be undervalued. The current stock price of CHF55.60 is trading 24.3% below its estimated GF Value™ of CHF73.46. GuruFocus considers Alcon to be Modestly Undervalued.

Key valuation signals for XSWX:ALCE:

  • Forward PE Ratio: 19.76
  • GF Value™: CHF73.46 vs. price of CHF55.60 (24.3% below fair value)
  • GF Score™: 53/100 with 3 warning signs
  • Industry Position: 4.8% above the Medical Devices & Instruments median (#211 of 393)

No single metric tells the full story. See the XSWX:ALCE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Alcon Business Description

Address Chemin de Blandonnet 8, Vernier, Geneva, CHE, 1214
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
53GF Score

Get the complete analysis for XSWX:ALCE

Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF55.60
Price
CHF73.46
GF Value